id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-P-1609-0004,FDA,FDA-2013-P-1609,"Determination That LUPRON DEPOT (Leuprolide Acetate for Depot
Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn
From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2014-10-08T04:00:00Z,2014,10,2014-10-08T04:00:00Z,,2015-03-24T20:25:17Z,2014-23961,0,0,09000064818b1b12
FDA-2013-P-1609-0003,FDA,FDA-2013-P-1609,"Citizen Petition Interim Response from FDA CDER to Lachman Consultant Services, Inc.",Other,Letter(s),2014-05-05T04:00:00Z,2014,5,2014-05-05T04:00:00Z,,2014-05-05T19:50:11Z,,0,0,09000064816e2b75
FDA-2013-P-1609-0001,FDA,FDA-2013-P-1609,"Lachman Consultant Services, Inc. - Citizen Petition",Other,Citizen Petition,2013-12-30T05:00:00Z,2013,12,2013-12-30T05:00:00Z,,2024-11-07T22:59:08Z,,1,0,09000064814ba5ba
FDA-2013-P-1609-0002,FDA,FDA-2013-P-1609,"Acknowledgement Letter to Lachman Consultant Services, Inc.",Other,Citizen Petition,2013-12-30T05:00:00Z,2013,12,2013-12-30T05:00:00Z,,2013-12-30T16:00:10Z,,0,0,09000064814ba662